149 related articles for article (PubMed ID: 7992079)
1. Somatostatin receptor imaging: a new horizon in the diagnostic management of neuroblastoma.
Sautter-Bihl ML; Dörr U; Schilling F; Treuner J; Bihl H
Semin Oncol; 1994 Oct; 21(5 Suppl 13):38-41. PubMed ID: 7992079
[No Abstract] [Full Text] [Related]
2. Somatostatin receptor scintigraphy (SRS): a new diagnostic tool in neuroblastoma (NB)?
Dörr U; Sautter-Bihl ML; Schilling FH; Koscielniak E; Treuner J; Bihl H
Prog Clin Biol Res; 1994; 385():355-61. PubMed ID: 7972231
[No Abstract] [Full Text] [Related]
3. [Eight year history of neuroblastoma in an adult patient. Value of 123I-MIBG and 111In-DTPA-D-Phe-octreotide scintigraphy].
Alonso Rodríguez M; Castejón Sánchez I; Mariño Pfeiffer E; Ramos Sanz J; Martínez García G; Escribano Arias M; Freile García I; Peiró Valgañón V; Ortiz Berrocal J
Rev Esp Med Nucl; 1999 Aug; 18(4):298-301. PubMed ID: 10481114
[TBL] [Abstract][Full Text] [Related]
4. I-131 MIBG scintigraphy of neuroectodermal tumors. Comparison between I-131 MIBG and In-111 DTPA-octreotide.
Lauriero F; Rubini G; D'Addabbo F; Rubini D; Schettini F; D'Addabbo A
Clin Nucl Med; 1995 Mar; 20(3):243-9. PubMed ID: 7750219
[TBL] [Abstract][Full Text] [Related]
5. Detection of neuroblastoma with 131I-meta-iodobenzylguanidine.
Voute PA; Hoefnagel CA; Marcuse HR; de Kraker J
Prog Clin Biol Res; 1985; 175():389-98. PubMed ID: 3991738
[No Abstract] [Full Text] [Related]
6. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C
J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058
[TBL] [Abstract][Full Text] [Related]
7. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
8. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid.
Dörr U; Sautter-Bihl ML; Bihl H
Semin Oncol; 1994 Oct; 21(5 Suppl 13):42-5. PubMed ID: 7992080
[No Abstract] [Full Text] [Related]
9. Somatostatin and the concept of peptide receptor scintigraphy in oncology.
Lamberts SW; Reubi JC; Krenning EP
Semin Oncol; 1994 Oct; 21(5 Suppl 13):1-5. PubMed ID: 7992074
[No Abstract] [Full Text] [Related]
10. Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.
Krenning EP; Kwekkeboom DJ; de Jong M; Visser TJ; Reubi JC; Bakker WH; Kooij PP; Lamberts SW
Semin Oncol; 1994 Oct; 21(5 Suppl 13):6-14. PubMed ID: 7992084
[No Abstract] [Full Text] [Related]
11. Somatostatin-receptor scintigraphy in Graves' orbitopathy.
Postema PT; Kwekkeboom DJ; van Hagen PM; Krenning EP
Eur J Nucl Med; 1996 Jun; 23(6):615-7. PubMed ID: 8662098
[No Abstract] [Full Text] [Related]
12. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor?
Kropp J; Hofmann M; Bihl H
Anticancer Res; 1997; 17(3B):1583-8. PubMed ID: 9179198
[TBL] [Abstract][Full Text] [Related]
13. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
Pauwels S; Leners N; Fiasse R; Jamar F
Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
[No Abstract] [Full Text] [Related]
14. Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas.
Schilling FH; Ambros PF; Bihl H; Martinsson T; Ambros IM; Borgström P; Jacobsson H; Falkmer UG; Treuner J; Kogner P
Med Pediatr Oncol; 2001 Jan; 36(1):56-60. PubMed ID: 11464907
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of 111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden.
Adrian HJ; Dörr U; Bach D; Bihl H
Horm Metab Res Suppl; 1993; 27():18-23. PubMed ID: 8330868
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor-based imaging in malignant lymphomas.
O'Brien JP
J Nucl Med; 1995 Jan; 36(1):19-20. PubMed ID: 7799074
[No Abstract] [Full Text] [Related]
17. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
Bernhardt P; Ahlman H; Nilsson O; Benjegård SA; Forssell-Aronsson E
Cancer Biother Radiopharm; 2003 Apr; 18(2):249-52. PubMed ID: 12804051
[No Abstract] [Full Text] [Related]
20. What is a false-positive somatostatin receptor scintigraphy?
Reubi JC
J Nucl Med; 1998 Dec; 39(12):2193-4. PubMed ID: 9867170
[No Abstract] [Full Text] [Related]
[Next] [New Search]
